Eli Radiopharma announces new financing round of nearly RMB 100 million to accelerate development and clinical translation of its novel target programs

On March 12, 2026, Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma", or "the Company"), an innovative radiopharmaceutical company focused on integrated diagnostics and therapeutics for oncology and neurological diseases, announced the completion of a new financing round of nearly RMB 100 million, with participation from Longfeng Venture, Echelon Capital, Hongsheng Capital, and Bioclub Fund. The proceeds will support the advancement of the Company's novel target programs, including molecular discovery, technology platform development, and clinical translation, advancing the Company's innovative pipeline toward the clinical stage.

"We are dedicated to addressing unmet clinical needs in oncology and neurological diseases by advancing a robust pipeline of innovative targets," stated Dr. Feng Yu, Founder and CEO of Eli Radiopharma. "At this stage, our lead molecules have been identified and validated in vitro and in vivo, with several demonstrating promising target specificity and drug development potential. This financing will accelerate R&D on these key targets and support our theranostics strategy, advancing differentiated programs toward clinical development."

"Radiopharmaceuticals are becoming an increasingly important modality in precision medicine, driven by strong global industry momentum and growing clinical demand," said an investor representative. "Eli Radiopharma has demonstrated solid capabilities in novel target discovery, molecular design, and clinical translation, with the potential to build a differentiated pipeline. Through this investment, we look forward to establishing a long-term partnership with the Company to support the advancement of its innovative pipeline and accelerate the clinical development of key programs."